Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.34 |
| ▸ | MEN1 | O00255 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 6/20 | 0.33 |
| ▸ | RAB9A | P51151 | 6/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.32 |
| ▸ | XBP1 | P17861 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5538471 | 0.93 | FGFR4 (0.40) | FGFR4F10KMT2AMEN1MAPT | |
| SCHEMBL5531792 | 0.92 | FGFR4 (0.39) | FGFR4F10KMT2AMEN1MAPT | |
| SCHEMBL5535284 | 0.92 | FGFR4 (0.39) | FGFR4F10KMT2AMEN1MAPT | |
| SCHEMBL5530778 | 0.92 | FGFR4 (0.42) | FGFR4F10KMT2AMEN1MAPT | |
| SCHEMBL5532013 | 0.84 | MEN1 (0.38) | FGFR4F10KMT2AMEN1MAPT | |
| SCHEMBL5530355 | 0.83 | F10 (0.41) | F10KMT2AMEN1NPC1RAB9A | |
| SCHEMBL5532926 | 0.81 | F10 (0.40) | F10KMT2AMEN1NPC1RAB9A | |
| SCHEMBL5533977 | 0.81 | F10 (0.43) | FGFR4F10KMT2AMEN1NPC1 | |
| SCHEMBL5536431 | 0.81 | F10 (0.46) | FGFR4F10 | |
| SCHEMBL5531871 | 0.80 | MAPT (0.44) | KMT2AMEN1MAPTHSD17B10NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312235-B2 | Benzamide inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | claimed |
| EP-1373194-B1 | BENZAMIDE INHIBITORS OF FACTOR Xa | MILLENNIUM PHARM INC (US) | 2007-08-01 | — | — | EP | claimed |
| US-20030069250-A1 | Benzamide inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-10 | — | — | US | claimed |
| US-7312235-B2 | Benzamide inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1373194-B1 | BENZAMIDE INHIBITORS OF FACTOR Xa | MILLENNIUM PHARM INC (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1373194-A1 | BENZAMIDE INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030069250-A1 | Benzamide inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2002079145-A1 | BENZAMIDE INHIBITORS OF FACTOR Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069250-A1 | Benzamide inhibitors of factor Xa | SERPINC1, TFPI, F12 | FGFR4 4054/4885F10 10/4885KMT2A 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.